Zolbetuximab sold under the brand name Vyloy, is a monoclonal antibody used for the treatment of gastric/gastroesophageal junction cancers.
It is a claudin 18.2-directed cytolytic antibody against isoform 2 of Claudin-18.
The most common adverse reactions include nausea, vomiting, decreased appetite, neutropenia, weight loss, fever, hypoalbuminemia and peripheral edema.
Zolbetuximab is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive.
Adverse effects: include nausea, vomiting, decreased appetite, neutropenia, weight loss, fever, hypoalbuminemia and peripheral edema.
Other side effects include hypertension, dyspepsia, chills, salivary hypersecretion, infusion-related reactions and hypersensitivity.